References
- Approved Prescription Drug Products with Therapeutic Equivalence Evaluation. Center for Drug and Biologics, Food and Drug Administration. 6th edition. Rockville, MD 1985
- Cany J. Why the FDA Needs a Miracle Drug. Business Week February 19, 1990
- Colan M. Getting it back on track. Drug Topics February 19, 1990; 42
- 1990, 21 C.F.R., Part 320 (1989). 21 CF.R.,S740(a)
- Fenesterer D., Mossinghoff G. J. Generics Vs. Brand-Name. Business Insurances September 12, 1988; 22(37)47
- Federal Register 1975; 40: 36, 142: 26,143
- Federal Register 1975; 40(26)148–149
- Federal Register 1980; 45(82)052, 46: 27,396(1981) 54: 28,872 (1989)
- Generic Industry Eyeing $8–$10 Billion Opportunity. Chemical Marketing Reporter April 22, 1991; 239(16)
- Generics Approval Seen Too Slow. Chemical Marketing Reporter April 22, 1991; 239(16)
- Mattison N. Pharmaceutical Innovation and Generics Drug Competition in the U.S.A.: Effects of the Drug Price Competition and Patent Term Restoration Act of 1984. Pharm. Med. 1986; 1: 177–85
- 1984, Public Law No. 98–147,98 Statute 1585
- Shah Hemant. Long-term Outlook is Good for Generics. Chain Drug Review October 10, 1989
- Silverman M. Pills, Profits and Politics. University of California Press, Berkeley 1974; 138–70
- Strom B. L., Stolley P. D., Brown T. C. Antisubstitution Law Controversy—A Solution. Ann. Intern Med. 1974, 81: 254–8
- Task Force on Prescription Drugs—Final Report. Government Printing Office, Washington, D.C. 1969; 36–37
- The Years in RXs-Flat but Hardly Drug. Drug Topics April 4, 1988; 132(7)24–33
- Zeiger M. The Generic Drug Industry: An Overview. Vital Speeches of the Day December 15, 1987; 54(5)142–47